Proportion of patients with various 10-year coronary heart disease thresholds (15%, 20% and 30%), compared with their eligibility for lipid-lowering drugs based on Australian PBS and NHF guidelines. Twenty-six per cent of patients with no history of vascular disease who are currently dispensed ...
Are the PBS guidelines for lipid-lowering treatment appropriate for patients with CHD?NUMEROUS reports during the past 25 years, including those of the American Medical Association's former Council on Foods and Nutrition,1-4 have discussed the relationship between diet and coronary heart disease (...
In contrast, the GOLDN (Genetics of Lipid-Lowering Drugs and Diet Network) study, which included 980 participants aged 18–87 years, discovered sex differences in plasma lipid levels, whereas our plasma lipidome in mice did not show a large sex difference25. In addition to human blood biopsy...
Inhibitors of intestinal TG absorption have been developed as effective lipid-lowering drugs. Lomitapide, an inhibitor of microsomal triglyceride transfer (MTT) protein that is critical in intestinal TG absorption, has been approved for use as a lipid-lowering agent. Other MTT inhibitors such as JTT...
Furthermore, having the advantage of harboring differentiated human hepatocytes, without any genetic changes, this model promises to be a tool for pharmacological studies of novel lipid lowering drugs that specifically act at the hepatocyte level. In addition, the model might be applied to study the...
Subjects with diabetes and clinical evidence of cardiovascular diseases or receiving antacids, lipid-lowering drugs, or antioxidant supplements were excluded from the study to avoid possible interferences on PON1 activity and plasma lipids. All subjects included in the study underwent upper ...
After PBS wash twice, cells were switched to 37 °C for the indicated time points. Scale bar 20 μm. t, Quantification of the internalized Dil-LDL in (s). The internalized Dil-LDL in WT cells at 0 h is defined as 0 (n = 45 cells). u, Silencing ASGR1 did not ...
5. Injection of PBS to sham-operated animals (Sham + PBS group) did not significantly change TNF-α level at the both 7 and 28 days after injection, compared to control group. Also, injection of MPL to sham-operated animals (Sham + MPL group) did not change TNF-α level ...
However, efficient drug delivery to treat ocular diseases, particularly intraocular disorders, remains a huge challenge due to multiple ocular barriers that significantly affect the ultimate therapeutic efficacy of drugs. Recent advances in nanocarrier technology offer a promising opportunity to overcome ...
Use of statins (lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, etc.), ezetimibe, Xuezhikang, and other lipid-lowering treatment within 2 months before screening; use of PCSK9 monoclonal antibodies, fibric acid drugs (such as ...